Avoiding the Need for Clinical-Grade OKT3: Ex Vivo Expansion of T Cells Using Artificial Antigen Presenting Cells Genetically Modified to Cross-Link CD3

MLA

Ang, S. O., et al. “Avoiding the Need for Clinical-Grade OKT3: Ex Vivo Expansion of T Cells Using Artificial Antigen Presenting Cells Genetically Modified to Cross-Link CD3.” Biology of Blood & Marrow Transplantation, vol. 18, no. 2, Feb. 2012, p. S258. EBSCOhost, https://doi.org/10.1016/j.bbmt.2011.12.159.

APA

Ang, S. O., Maiti, S. N., Hartline, C., Olivares, S., Huls, H., Champlin, R., & Cooper, L. J. N. (2012). Avoiding the Need for Clinical-Grade OKT3: Ex Vivo Expansion of T Cells Using Artificial Antigen Presenting Cells Genetically Modified to Cross-Link CD3. Biology of Blood & Marrow Transplantation, 18(2), S258. https://doi.org/10.1016/j.bbmt.2011.12.159

Chicago

Ang, S.O., S.N. Maiti, C. Hartline, S. Olivares, H. Huls, R. Champlin, and L.J.N. Cooper. 2012. “Avoiding the Need for Clinical-Grade OKT3: Ex Vivo Expansion of T Cells Using Artificial Antigen Presenting Cells Genetically Modified to Cross-Link CD3.” Biology of Blood & Marrow Transplantation 18 (2): S258. doi:10.1016/j.bbmt.2011.12.159.